Muggia, F.M.

University of California, Irvine · NYU Langone Health · Massachusetts General Hospital · Assistance Publique – Hôpitaux de Paris · Antwerp University Hospital · Royal Marsden Hospital · New York University · Columbia University

2 papers on CoChatORCID 0000-0003-0703-9146

Most cited papers

Verified
Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil®): possible role in hypersensitivity reactions
Chanan-Khan, A., Szebeni, J., Savay, S., Liebes, L., Rafique, N. M., Alving, C. R., & Muggia, F. M. (2003) · Annals of Oncology
Complement system in diseasesDrug-Induced Adverse Reactions
Cited by 479
Verified
Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer
Monk, B. J., Herzog, T. J., Kaye, S. B., Krasner, C. N., Vermorken, J. B., Muggia, F. M., Pujade-Lauraine, E., Lisyanskaya, A. S., Makhson, A. N., Rolski, J., et al. (2010) · Journal of Clinical Oncology
Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapy
Cited by 395

Go further with a free account

Verify every reference, keep papers in a library, and ask questions across them.

Sign up - it is free